Growth strong, profits lag—the commodity discount looms
Revenue jumped 30%, but profit rose only 8%, with EBITDA margin compressed 120 basis points. The gap reveals where this quarter really stands: strong orders, weak profits, margin recovery betting entirely on uncertain OEM cost-sharing settlements.
₹4,315 Cr
+30% YoY
₹244.5 Cr
+8% YoY
120 bps
EBITDA: 13.1% vs. 14.3% prior year
−11.6%
Sequential decline signals ramp-up drag
On its face, Endurance delivered a strong quarter: consolidated revenue of ₹4,315 Cr is up 30% year-over-year, and the company landed its result target. But look at the profit growth—8% PAT expansion on 30% revenue growth—and the story inverts. Margin compression of 120 basis points (EBITDA 13.1% vs. 14.3% prior year) and a sequential PAT decline of 11.6% quarter-on-quarter expose a company running hard just to stay in place. The quarter reveals a widening gap between what the order book promises and what the P&L delivers.
Where the margin went
Management attributes the profit shortfall to commodity headwinds. Raw materials and consumables as a percentage of revenue jumped to 68.4% from 64.8% in the prior year—a 360 basis point surge. This spike, management claims, was driven by West Asia conflict, aluminium and steel cost surges, and fuel inflation, resulting in ₹300 Cr paid upfront by Endurance in the quarter due to quarter-lag accounting (OEM customers slow to reimburse). If this claim holds, the adjusted EBITDA margin would be 13.33%, not the reported 11.2% standalone—a 213 basis point difference. The problem: the ₹300 Cr figure is plausible but unverified, and the recovery—promised for Q2 and Q3 via OEM cost-sharing settlements—remains unquantified. Management explicitly refused to project the benefit magnitude, citing 'too many variables.' That caution is candid but alarming: it signals management itself is uncertain whether OEM partners will fully absorb their share of the commodity lag.
Consolidated PAT grew 8%; EBITDA margin improved to 13.1%
PAT +8% YoY ✓; but EBITDA margin compressed 120 bps from 14.3% (not improved)
Overstated on margin
Revenue grew 35.9% standalone, 29.6% consolidated
Consolidated ₹4,315 Cr (+30% YoY); aligned with stated guidance
Supported
₹300 Cr commodity paid upfront; adjusted EBITDA would be 13.33%
RMC % jumped 360 bps (64.8% → 68.4%). Calculation plausible; OEM pass-through timing unconfirmed
Plausible but unverified
Maxwell achieved PAT positive for first time with 85% income growth
Maxwell income ₹56.5 Cr (Q1 FY27) vs. ₹30.5 Cr (Q1 FY26) = 85% YoY ✓
Supported
EV sales India grew 87.6% to ₹129.7 Cr
From ₹69.2 Cr (Q1 FY26) to ₹129.7 Cr (Q1 FY27) = 87.4% ✓
Supported
What changed on this call
4W segment expanded into new geographies and OEMs. Prior calls aspired to 10% of revenue; Q1 achieved ₹180 Cr (6% of standalone revenue). New wins: Hyundai/Kia ₹80 Cr per annum, Shendra facility ₹513 Cr per annum (peak by FY29), Isuzu hybrid, Tata/Mahindra Chakan growth. Path to double-digit 4W revenue now credible.
Battery packs entered as a new forward-integrated segment. Prior calls detailed Battery Management Systems (Maxwell) only. Q1 added 2W battery pack manufacturing for Hero MotoCorp (ramping to 18K units/month) and 4W pack capex (₹62 Cr for Q4 FY27 SOP). This is incremental revenue not previously modeled.
Capex guidance held steady despite customer capex upgrades. Bajaj, Royal Enfield, TVS upgraded capex in Q1, but Endurance reiterated ₹800 Cr (same as FY26). Rationale: already have capacity; outsource to strong Tier-2 vendors. Dynamic situation (can increase if large wins emerge). No guidance shift.
Europe order book declining; Chinese OEM competition cited. Prior calls showed stable European order wins. Q1 revealed Chinese OEMs (SAIC +32%, BYD +167%, Chery +272%, Leapmotor +500% YoY) taking share via imports. Endurance won Mercedes 100% of hybrid transmission (previously 60%), offsetting some volume risk. Net: opportunity within challenge.
The bull-bear ledger
Order book is massive and diverse. ₹4,526 Cr of RFQ in hand (not committed, but serious pipeline), ₹513 Cr Shendra casting orders (long lead, peak by FY29), ₹238 Cr Maxwell BMS cumulative orders. Multiple customer wins (Hyundai, Kia, Tata, Mahindra, global OEMs) breaking HMSI concentration.
Multiple high-value SOPs on schedule (Q2–Q4). ABS dual-channel Bajaj (Q2, 120K units/annum), Tata 4W brakes (Q2), Shendra casting (Sept 2026), battery pack 4W (Q4). Execution track record strong (brake business CAGR 30% over 4 years).
EV exposure growing fast. EV revenue India +87.6% to ₹129.7 Cr; consolidated EV+PHEV +20.9% to ₹931.9 Cr (21% of total revenue). Structural tailwind as scooter penetration rises (+32.7% YoY) and 2W electrification accelerates.
Market share expansion across core segments. Brakes 34.5% (assembly), 42% (disc), front forks 44%, shock absorbers 37%. New segments (4W castings, battery packs, solar dampers) entering high-value niches.
Profit growth lagged revenue by 22 percentage points. 30% revenue growth vs. 8% PAT growth is a red flag for leverage. Sequential PAT fell 11.6% (implied ₹28 Cr drop), unaddressed by management. Signals ramp-up drag and commodity accounting lag are real, not transient.
Margin recovery is unquantified and contingent. Management refused to forecast Q2–Q3 cost pass-through benefit, citing 'too many variables.' This is honest but risky: if OEM settlement talks stall or result in partial recovery, profitability momentum stalls with them.
Customer concentration remains acute. HMSI represents 85% of Q1 order wins (₹336 Cr of ₹391.6 Cr). While diversification into TVS, Bajaj, Tata, Mahindra is underway, HMSI growth hiccup = revenue hiccup for Endurance. Risk acknowledged but not yet mitigated.
New plants operating far below peak efficiency. Bidkin alloy wheel plant at 60% utilisation (1.8M sets capacity), battery pack plant scaling. These dilute consolidated profitability until full ramp (guided for Q3–Q4 FY27). If ramps slip, profitability recovery pushes to Q1 FY28 or beyond.
Europe order book stalling. Revenue €104.3M (+1.1% YoY only), EBITDA margin 18.2%, but PAT down 31% due to ICE asset depreciation. Chinese OEM production in Europe up 32–500% YoY; traditional German OEM volumes under pressure. Endurance winning selectively (Mercedes), but market TAM at risk.
How the market is treating this
The price action speaks. On day 1 after the result announcement, the stock fell 2.88% (delivery 97.5%, indicating strong institutional selling pressure). It recovered 1.12% by day 3, then only 0.56% by day 5. The full recovery has not held, suggesting the market remains skeptical of near-term margin recovery. Current price of ₹3,029.5 sits −1.38% from its all-time high of ₹3,072, with RSI at 71.1 (overbought territory). Foreign institutional investors trimmed by 0.44 percentage points in Q1 (FII holdings 12.70% vs. 13.14% in Q4), a subtle but meaningful signal: smart foreign money is taking profits on momentum rather than buying dips. The stock has rallied 41.38% from its 52-week low (₹2,142.8), and at current valuations (RSI 71), the market is pricing in SOP execution perfection and full commodity pass-through recovery. The day-1 selloff and FII trim suggest that's not yet priced fairly.
Ranked risks—what should concern a holder
OEM cost-sharing settlements slip or arrive only partial
HIGH₹300 Cr of Q1 profit was sacrificed in the quarter on the promise of recovery in Q2–Q3. If OEM negotiations drag or result in 50–70% recovery instead of 100%, profit growth stays flat and margin recovery is delayed by 1–2 quarters. Management's explicit refusal to quantify the benefit signals internal uncertainty.
Multiple SOP execution delays (Q2–Q4 programme slip)
MEDIUMShendra Sept 2026, ABS Q2, battery packs Q4, etc. are the ramp drivers for profitability growth in H2 FY27. Any slip of >1 quarter delays both revenue and margin accretion. Company has a track record of on-time execution (brake CAGR 30%), but new-to-company battery and casting platforms add execution risk.
European market headwind accelerates; Chinese OEM competition bites
MEDIUMEurope revenue is already flat (+1.1% YoY). If Chinese OEM localization in Europe accelerates (already +32–500% growth) and German OEMs (Mercedes, VW) close ICE platforms faster than expected, Endurance's Europe TAM shrinks. Mercedes 100% win is a one-off offset; it doesn't reverse the trend.
HMSI concentration materializes as volume risk
MEDIUMHMSI = 85% of Q1 order wins. HMSI's growth slows (motorcycles market growth 19.3% YoY, decelerating) or OEM decides to in-house or switch suppliers = significant revenue/margin hit for Endurance. Diversification into Tata/Mahindra/Bajaj ongoing but not yet proportionate.
Ramp-up margin drag persists longer than Q3–Q4
MEDIUMBidkin (60% utilised) and battery pack plants (scaling) are diluting consolidated profitability. If customer ramps slip, these facilities stay underutilised into Q1 FY28, extending the PAT growth drag. Consolidated PAT growth (8% YoY) is already lagging standalone (17.4%) due to this.
Commodity price volatility reverses (i.e., costs fall faster than OEMs pass back)
LOWIf aluminium, steel, fuel prices fall sharply in Q2–Q3, OEM customers may demand retroactive price cuts on products already sold, offsetting the settlement gains Endurance is counting on. Lower severity because commodity spikes (not drops) are the historical norm, but tail risk to watch.
The debate
What to watch next
1 · Q2 OEM cost-sharing settlements—the wildcard
Management guided margin recovery 'Q2 and Q3 for sure' but refused to quantify. Watch the Q2 result for signs of RMC % improving, EBITDA margin expanding, and management commentary on settlement success rate (full vs. partial). If Q2 RMC % remains >68% and management pushes recovery to Q3, the thesis breaks. If RMC % improves to <65% and margin expands 100+ bps, the bull case re-engages.
2 · SOP execution and ramp profitability
Shendra facility should ship its first customer orders in Sept 2026. Monitor Q3 FY27 results for Shendra revenue contribution and gross margin (should be accretive given it's a greenfield, high-value casting facility). ABS SOP for Bajaj should be live in Q2; battery pack 2W for Hero should ramp to 18K units/month by October. Any slip here delays both revenue and profitability accretion by 1–2 quarters.
3 · Bidkin alloy wheel and battery pack utilisation trajectory
These plants are currently at 60% and scaling, respectively. Watch for Q2/Q3 commentary on utilisation rates moving toward 80%+. If Bidkin and battery plants reach full capacity (end of Q3 or Q4), consolidated margin will jump because ramp-up drag ends. This is the margin lever management is betting on.
The number to track
Not revenue. Revenue is steady—30% growth is credible given the order book. Track consolidated EBITDA margin in Q2. If it expands back to ≥14% (or approaches it), cost pass-through is working and the bull case re-engages. If it stays <12.5%, OEM settlements are slipping or partial, and profitability recovery is at risk. That single metric—margin expansion—is everything from here.
Endurance has assembled a strong multi-year order book and is diversifying into high-value EV segments—battery packs, 4W castings, advanced braking systems. The structural story is sound. But this quarter exposed a gap between growth and profitability that can't be ignored. Revenue growth and profit growth have decoupled, and management is betting it's temporary—a commodity lag that OEMs will absorb in Q2 and Q3. That's plausible. It's also unquantified, unconfirmed, and contingent on OEM negotiation success. The market's day-1 selloff (−2.88%) and FII trim suggest smart money is skeptical. At an RSI of 71 near all-time highs, the stock is priced for SOP execution perfection and full cost pass-through recovery. Until Q2 results prove that recovery is materializing, this is a Hold. The single number that flips the verdict: consolidated EBITDA margin recovery to ≥14% in Q2. Watch for it.
Informational and educational content only. Not investment advice.